Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Next generation CAR-T
Company stage: Clinical
Diseases: Adult T-cell acute lymphoblastic leukaemia (T ALL), others undisclosed
Genome editing technology: CRISPR-Cas9
Funding stage: Public (NASDAQ:GRCL)
Location: Suzhou, China and Palo Alto, CA, USA
Gracell Biotechnologies is a clinical-stage CAR-T focused company. Its pipeline is derived from two proprietary technology platforms: the FasTCAR and TruUCAR platforms. FasTCAR is an autologous-based platform that allows for improved manufacturing speed and quality as well as improved T-cell fitness. TruUCAR is an allogeneic, off-the-shelf-based platform. Here, CRISPR-Cas9 is used to knock out the T cell receptor (TCR) and specific tumour antigens in allogeneic CAR-T products. One TruUCAR-based programme has so far entered a clinical trial.